March 9, 2010 (FinancialWire) — MDS Inc. (TSX: MDS) (NYSE: MDZ) said it has completed the divestiture of its MDS Pharma Services Early Stage business.

Company CEO Steve West said, “The completion of this transaction marks the end of the company’s strategic repositioning and enables us to move forward with a focus on MDS Nordion.”

MDS said it is providing transition services to the buyers of the businesses it has sold and has initiated the relocation of its corporate headquarters to Ottawa, Canada. These activities are scheduled to be substantially complete by the end of 2010.

The divestiture of the MDS Pharma Services Early Stage business does not include the facility in Montreal, Canada, which is expected to be closed by the end of February 2011.

Canada-based MDS is a global health science company that provides products and services used for the prevention, diagnosis and treatment of disease.

The company is a provider of technologies for use in medical imaging and radiotherapeutics, and sterilization technologies.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.